A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs)

  Measured over: Up to Approximately 24 months

• Randomized Phase 2 Cohort: Percentage of Participants who Achieved Objective response rate (ORR)

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Maximal Concentration (Cmax) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Area Under the Plasma Concentration (AUC) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Trough Concentration (Ctrough) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Volume of Distribution at Steady State (Vss) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Time to Maximal Concentration (Tmax) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

• Hepatic Impairment Cohort: Terminal Half-Life (t1/2) of Mirvetuximab Soravtansine

  Measured over: Up to Approximately 24 months

Changes Tremor has spotted